Experimental studies at Southern Research Institute with DTIC (NSC-45388).
Several years ago the diazotization of 5-aminoimidazole-4-carboxamide was found to give an internal diazonium salt, 5-diazoimidazole-4-carboxamide, which demonstrated marginal activity against some murine neoplasms. In an effort to improve this activity and develop a clinically useful agent, this compound was converted to a number of derivatives including DTIC, an agent that showed encouraging activity against a variety of rodent neoplasms. Studies carried out at Southern Research Institute on the chemistry, metabolism, and biologic activity of DTIC and its congeners are discussed briefly.
D000818:Animals; D002460:Cell Line; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats; D014226:Triazenes / Q000627:therapeutic use*
D014226:Triazenes; D003606:Dacarbazine; D004317:Doxorubicin